While Medtronic Enterra Therapy has been available to patients since 2000, the new Enterra II system provides physicians with greater system flexibility and ease-of-use.
Gastroparesis is a serious stomach disorder with many possible causes, including diabetes, and is characterized by stomach muscles that work poorly or not at all, slowing or stopping the movement of food from the stomach to the small intestine.
“This device is an important option for people suffering from the severe effects of gastroparesis,” says Henry P. Parkman, MD, Professor of Medicine at Temple University School of Medicine, and Director of the GI Motility Laboratory at Temple University Hospital. “Temple University Hospital is one of the nation’s most comprehensive centers for the diagnosis and treatment of digestive disorders, and we are pleased to be the first in the region to be able to offer this to our patients.”
Medtronic Enterra Therapy is for patients 18 to 70 years old and is used when more conservative treatments fail or cannot be tolerated. While the patient is under general anesthesia, the surgeon implants a small medical device called a neurostimulator under the skin, usually in the lower abdominal region. Two insulated wires, called leads, are implanted in the stomach wall muscle and then connected to the neurostimulator, which delivers mild electrical pulses through the leads to stimulate the smooth muscles of the lower stomach.
After the device is implanted, the doctor uses a handheld, external programmer to noninvasively adjust the neurostimulator and customize the stimulation to each patient’s needs. Medtronic Enterra Therapy can be turned on and off at any time using the physician programmer. The patient generally remains in the hospital for 2-3 days after the surgery.
The Enterra II System features an improved user interface for device programming, improvements to the system’s battery-life indicator, and a customized tool that simplifies implantation of the device for physicians.
This device was recently approved by the U.S. Food and Drug Administration under a humanitarian device exemption.
Editor’s Note: Neither Dr. Parkman nor any member of his immediate family has financial interest in Medtronic, Inc.
About Temple Health
Temple University Health System (TUHS) is a $1.4 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH), ranked among the “Best Hospitals” in the region by U.S. News & World Report; TUH-Episcopal Campus; TUH-Northeastern Campus; Fox Chase Cancer Center, an NCI-designated comprehensive cancer center; Jeanes Hospital, a community-based hospital offering medical, surgical and emergency services; Temple Transport Team, a ground and air-ambulance company; and Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices. TUHS is affiliated with Temple University School of Medicine.
Temple University School of Medicine (TUSM), established in 1901, is one of the nation’s leading medical schools. Each year, the School of Medicine educates approximately 840 medical students and 140 graduate students. Based on its level of funding from the National Institutes of Health, Temple University School of Medicine is the second-highest ranked medical school in Philadelphia and the third-highest in the Commonwealth of Pennsylvania. According to U.S. News & World Report, TUSM is among the top 10 most applied-to medical schools in the nation.
Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by Temple University School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.